PMA device
VISTAKON® (senofilcon A) Brand Contact Lenses
Vistakon, Division of Johnson & Johnson Vision Car · Lenses, Soft Contact, Extended Wear (LPM, Class III) · First FDA decision Jan 16, 2014, newest Sep 22, 2022Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "VISTAKON Brand"
MAUDE reports
0
Brand "VISTAKON Brand", since 2015
PubMed studies
0
Mentioning "VISTAKON Brand"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VISTAKON® (senofilcon A) Brand Contact Lenses
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- VISTAKON® (senofilcon A) Brand Contact LensesPMA supplement
P040045-S127 · Decided Sep 22, 2022 · 90 days after receipt · Normal 180 Day Track
Device type: Lenses, soft contact, extended wear (LPM) · Ophthalmology
- VISTAKON (SENOFILCON A) BRAND CONTACT LENSESPMA supplement
P040045-S041 · Decided Jan 16, 2014 · 59 days after receipt · Normal 180 Day Track
Device type: Lenses, soft contact, extended wear (LPM) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hydrophilic Contact LensesNational determinationOn the books80.4Updated Jun 11, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "VISTAKON Brand", any status and sponsor, newest update first.
No registered device study names "VISTAKON Brand".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VISTAKON Brand", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LPM
1,788 reports: 19 malfunction, 1,759 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Johnson & Johnson Vision Care, Inc.
Z-1209-2018 · Started Oct 19, 2017
Reason given: Some contact lenses were associated with complaints of a foreign matter caught between the blister package and foil.
Cause as FDA categorized it: Packaging process control · Device type: Lenses, Soft Contact, Extended Wear (LPM)
Published research
The most relevant PubMed records for "VISTAKON Brand"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LPM.
- Bausch and Lomb Polymacon Hydrophilic Contact LensesBausch & Lomb, Inc. · PMA 2002
- methafilcon A Soft (Hydrophilic) Extended Wear Contact LensesCooperVision, Inc. · PMA 2019
- Biofinity (Confilcon A) Soft Contact LensesCooperVision, Inc. · PMA 2012
- Sofmed® breathables XW NEXTCooperVision, Inc. · PMA 2025
- up&up Monthly Performance +CooperVision, Inc. · PMA 2025
- VISTAKON® (etafilcon A) Brand Contact LensesVistakon, Johnson & Johnson Vision Products, Inc. · PMA 2022
- Ethos AquaTech Monthly XR, Ethos AquaTech Monthly XR for AstigmatismCooperVision, Inc. · PMA 2022
- Natural Eyes HydraWear XW Extended ParametersCooperVision, Inc. · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.